Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib

Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib

Novel anaplastic lymphoma kinase (ALK) fusions are still being discovered in non-small cell lung cancer (NSCLC). Most patients with ALK+ NSCLC respond favorably to ALK tyrosine kinase inhibitors. In this case report, we identified a novel nonreciprocal ALK fusion, namely, junctional sarcoplasmic ret...

Full description

Bibliographic Details
Main Authors: Feng Xue, Shengyuan Xu, Cailing Jiang, Mafei Kang, Muhammad Usman, Lin Zhu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Oncology
Subjects:
intergenic region-ALK fusion
non-small cell lung cancer
alectinib
targeted therapy
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1019624/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1019624/full

Similar Items